


# Financial Highlights

Shionogi has adopted International Financial Reporting Standards (IFRS) from fiscal 2019. The financial figures for fiscal 2018 are shown according to both Japanese Generally Accepted Accounting Principles (JGAAP) and IFRS.


## Revenue




■ Revenue

Revenue was ¥297.2 billion, down 10.9% year on year. Domestic prescription drug sales and exports/overseas subsidiary sales were ¥94.7 billion (down 10.9% year on year) and ¥24.6 billion (down 20.0% year on year), respectively, due to the impact of changes in the business environment during COVID-19. Royalty income related to anti-HIV agents from Viiv Healthcare Ltd. was ¥123.4 billion (down 3.7% year on year), due to the effect of exchange rate movements.

## R&D expenses




## Operating profit/Operating profit margin




Operating profit was ¥117.4 billion (down 10.1% year on year), due to higher R&D investments in key projects and projects related to COVID-19. Excluding special items, such as the gain on exchange from redevelopment of the Shionogi Shibuya Building, core operating profit was ¥94.0 billion (down 26.2% year on year).

## Royalty income




Royalty income was ¥144.6 billion (down 13.3% year on year). Although ViiV Healthcare’s global sales of the anti-HIV agents *Tivicay*, *Triumeq*, *Juluca*, and *Dovato* remained firm, exchange rate movements caused sales to decline of 3.7% year over year. Other reasons for the decline were the absence of milestone payments received from Roche in the previous year in connection with progress in global development of *Xofluz* and lower receipts of royalty income from *Crestor* sales since the fourth quarter of fiscal 2020 under the terms of the license agreement with AstraZeneca.

## Dividends per share/DOE



Dividends per share were ¥108, up ¥5 from the previous year and our ninth consecutive year of dividend growth. DOE was 4.1%, exceeding our KPI of 4.0%.

## ROE



ROE was 13.9%, exceeding our KPI of 12.5%. This was primarily because, while ROE declined with the adoption of IFRS, this was due to an increase in equity items (equity attributable to owners of parent).

# Non-Financial Highlights

## Code of Conduct signature rate (FY2020)

100%


\* Shionogi & Co., Ltd. and its domestic group companies, with some exceptions

## Education and training expenses per person (FY2020)

¥140 thousand

\*(Education and training expenses + amount of self-investment support)/number of employees (Nonconsolidated)

## Acquisition rate of childcare leave




FY2022 target (Male)

Acquisition rate of childcare leave/days off for childcare purposes of 50% or more

## External evaluations

	FY2018	FY2019	FY2020
CDP	Climate change: C Water: No rating	Climate change: A- Water: A	Climate change: A- Water: A
FTSE	Not selected/2.9	Not selected/2.9	Selected/3.4
MSCI	A	AA	AA
DJSI	No response/17 points	No response/19 points	Response/45 points
S&P/JPX Carbon Efficient Index	Third decile	Third decile	Fourth decile
Toyo Keizai CSR Ranking	51st of 1,501 companies	63rd of 1,593 companies	34th of 1,614 companies
SOMPO Sustainability Index	Selected	Selected	Selected
Survey on Health and Productivity Management	Health and Productivity Stocks White 500	White 500	White 500

## GHG emissions (Scope 1 and 2)



FY2030 target\*


FY2050 target

down 46.2% (FY2019 benchmark)

Zero

\* The base year (FY2019) emissions for the FY2030 target (SBT) were 82,209 tons-CO<sub>2</sub>, including the FY2019 emissions of UMN Pharma Inc. and Nagase Medicals Co., Ltd.

## Ratio of female managers



FY2022 target (domestic consolidation)

At least 15% of women occupying management positions

## At a glance

■ Ratio of operating profit to revenue (FY2020)

**39.5%**

■ ROE (FY2020)

**13.9%**

■ Ratio of drugs discovered in-house (as of March 31, 2021)

**71%**


■ Infectious disease (COVID-19) pipeline (as of Aug. 2021)

Area	Pipeline	Indication	Status
Infectious disease (COVID-19)	S-268019	Prevention of COVID-19	Japan: Phase 1/2
	S-217622	Treatment of COVID-19	Japan: Phase 1
	S-555739 (asapirant)	Control of the aggravation of COVID-19	US: Phase2

■ 8 core pipeline projects (as of Aug. 2021)

Area	Pipeline	Indication	Status
Infectious disease	S-540956	① Infectious disease ② Cancer	Preparing for Phase 1 clinical trials
Pain/CNS	S-600918 (sivopixant)	① Refractory/unexplained chronic cough ② Sleep apnea syndrome	① Phase 2b clinical trials in progress ② Phase 2a clinical trials in progress
	S-637880	Neuropathic low back pain	Phase 2a clinical trials in progress
	S-812217 (zuranolone)	Depression	Phase 2a clinical trials in progress
	BPN14770 (zatolmilast)	① Alzheimer's disease ② Fragile X syndrome	① Phase 2 clinical trials in progress ② Preparing for US Phase 2b and Phase 3 clinical trials
	S-874713	Psychoneurological diseases	Preparing for Phase 1 clinical trials
New growth areas	S-531011	Solid tumors	Preparing for Phase1b/2 clinical trials
	S-005151 (redasemtide)	① Epidermolysis bullosa ② Stroke ③ Osteoarthritis ④ Chronic liver disease	① Preparing for application ② Phase 2 clinical trials in progress ③④ Investigator-initiated trials (Phase 2 clinical trials) in progress

■ Proportion of R&D expenses for the infectious disease area (FY2020)



\* Labor costs and indirect spending not included.

# 11-Year Financial Summary

## Third Medium-Term Business Plan

SONG for the Real Growth  
Progress toward global growth

Grow as a drug discovery-based  
pharmaceutical company  
(FY2014-September FY2016)

JGAAP	2011	2012	2013	2014	2015	2016
<b>For the years ended March 31:</b>						
Net sales	¥282,350	¥267,275	¥282,903	¥289,717	¥273,991	¥309,973
Cost of sales	81,737	77,753	78,574	77,993	82,189	74,758
Selling, general and administrative expenses	153,720	142,518	144,764	149,848	141,436	143,808
Operating income	46,892	47,003	59,565	61,875	50,365	91,406
Ordinary income	45,176	46,093	58,922	62,225	77,880	100,869
Profit before income taxes	33,135	41,494	58,306	63,188	82,051	97,452
Profit attributable to owners of parent	20,026	27,101	66,727	40,618	44,060	66,687
Net cash provided by operating activities	56,528	54,724	59,276	79,496	45,604	102,290
Net cash used in investing activities	(13,947)	(38,290)	(19,959)	(20,040)	(31,696)	(32,894)
Net cash used in financing activities	(27,011)	(27,749)	(37,687)	(53,798)	(46,211)	(18,525)
Research and development expenses	50,921	53,599	53,021	53,605	48,870	49,787
Capital investments	17,967	13,233	11,447	8,962	8,163	9,943
Depreciation and amortization	17,966	16,282	11,912	12,912	12,672	12,578
<b>As of March 31:</b>						
Property, plant and equipment, net	¥ 70,220	¥ 74,282	¥ 78,473	¥ 78,976	¥ 77,022	¥ 78,673
Intangible assets	99,593	106,694	70,464	72,824	80,328	71,626
Total assets	523,242	522,161	574,882	580,566	595,067	631,599
Total long-term liabilities	115,325	92,899	53,041	33,721	48,427	45,739
Total net assets	328,096	347,198	423,633	467,836	478,883	513,877
<b>Per share amounts:</b>						
Profit attributable to owners of parent	¥ 59.80	¥ 80.93	¥ 199.25	¥ 121.29	¥ 132.67	¥ 204.83
Net assets	979.69	1,027.83	1,254.44	1,385.11	1,456.70	1,564.73
Dividend	40	40	42	46	52	62
<b>Other:</b>						
Equity ratio	62.7	65.9	73.1	79.9	79.7	80.7
Return on equity [ROE]	6.0	8.1	17.5	9.2	9.4	13.6
Payout ratio	66.9	49.4	21.1	37.9	39.2	30.3

Notes: 1. From the fiscal year ended March 31, 2015, the Company has adopted a new accounting standard for research and development expenses (business research expenses). This change has been reflected in figures for the fiscal year ended March 31, 2014.

2. In the fiscal year ended March 31, 2019, the Company changed the presentation method for tax effect accounting. The change has been reflected in figures for the fiscal year ended March 31, 2015, and subsequent periods.

3. International Financial Reporting Standards (IFRS): Accounting standards defined by the non-government organization International Accounting Standards Board (IASB) headquartered in London.

4. IFRS adopted from the fiscal year ended March 31, 2020.

## Shionogi Growth Strategy 2020 (SGS2020)

Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare (October FY2016-FY2019)

## Shionogi Transformation Strategy 2030 (STS2030)

Building Innovation Platforms to Shape the Future of Healthcare

2017	2018	2019	International Financial Reporting Standards (IFRS)	2019	2020	2021	2021
(Millions of yen)			<b>For the years ended March 31:</b>		(Millions of yen)		(Thousands of U.S. dollars)
¥338,890	¥344,667	¥363,721	Revenue	¥367,960	¥333,371	¥297,177	\$2,684,290
77,777	73,911	54,880	Cost of sales	(55,591)	(56,782)	(52,523)	(474,426)
152,934	155,537	170,303	Selling, general and administrative expenses	(87,668)	(95,094)	(91,902)	(830,122)
108,178	115,219	138,537	Research and development expenses	(52,058)	(47,949)	(54,249)	(490,018)
123,031	138,692	166,575	Operating profit	145,081	130,628	117,438	1,060,772
122,695	137,378	170,343	—	—	—	—	—
83,879	108,866	132,759	Profit before tax	174,043	158,516	143,018	1,291,833
111,903	129,790	145,684	Profit attributable to owners of parent	137,191	122,193	111,858	1,010,377
(31,643)	(51,238)	(36,349)	Net cash provided by operating activities	165,000	131,940	109,039	984,911
(57,411)	(53,893)	(87,011)	Net cash used in investing activities	(56,256)	(29,144)	(5,261)	(47,528)
59,907	59,945	68,325	Net cash used in financing activities	(89,912)	(88,174)	(43,891)	(396,452)
9,659	5,678	7,900	Capital investments	7,900	9,954	27,371	247,232
13,362	15,972	16,479	Depreciation and amortization	14,431	14,115	14,779	133,494
(Millions of yen)			<b>As of March 31:</b>		(Millions of yen)		(Thousands of U.S. dollars)
¥ 78,788	¥ 75,956	¥ 74,653	Property, plant and equipment, net	¥ 70,986	¥ 71,350	¥ 90,883	\$ 820,918
91,125	75,060	54,769	Intangible assets	47,804	51,705	76,558	691,522
661,499	711,463	778,741	Total assets	938,540	873,695	998,992	9,023,512
44,692	34,056	17,203	Total equity	813,087	765,203	864,550	7,809,149
526,211	604,840	672,429	Non-current liabilities	29,303	27,372	34,261	309,471
(Yen)			<b>Per share amounts:</b>		(Yen)		(U.S. dollars)
¥ 259.88	¥ 342.71	¥ 424.31	Basic earnings per share	¥ 438.47	¥ 395.71	¥ 365.03	\$3.30
1,638.46	1,911.36	2,144.33	Equity attributable to owners of parent per share	2,598.16	2,518.74	2,806.67	25.35
72	82	94	Dividend	94	103	108	0.98
(%)			<b>Other:</b>		(%)		
79.0	84.5	85.7	Ratio of equity attributable to owners of parent	86.2	87.6	84.7	
16.3	19.4	20.9	Return on equity attributable to owners of parent (ROE)	17.8	15.5	13.9	
27.7	23.9	22.2	Payout ratio	21.4	26.0	29.6	

# Consolidated Financial Statements

## Consolidated statement of financial position

	As of March 31, 2020	(Millions of yen) As of March 31, 2021	(Thousands of U.S. dollars) As of March 31, 2021
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	¥ 71,350	¥ 90,883	\$ 820,918
Goodwill	7,854	9,357	84,525
Intangible assets	51,705	76,558	691,522
Right-of-use assets	4,657	4,827	43,605
Investment property	2,496	26,759	241,704
Other financial assets	202,161	217,437	1,964,028
Deferred tax assets	3,048	11,729	105,952
Other non-current assets	14,394	5,200	46,978
<b>Total non-current assets</b>	<b>357,669</b>	<b>442,754</b>	<b>3,999,232</b>
<b>Current assets</b>			
Inventories	33,818	38,003	343,271
Trade receivables	79,804	78,047	704,969
Other financial assets	171,157	142,151	1,284,002
Income taxes receivable	192	164	1,487
Other current assets	22,191	21,697	195,984
Cash and cash equivalents	208,861	276,173	2,494,567
<b>Total current assets</b>	<b>516,026</b>	<b>556,238</b>	<b>5,024,280</b>
<b>Total assets</b>	<b>873,695</b>	<b>998,992</b>	<b>9,023,512</b>

	As of March 31, 2020	(Millions of yen) As of March 31, 2021	(Thousands of U.S. dollars) As of March 31, 2021
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital	¥ 21,279	¥ 21,279	\$ 192,212
Capital surplus	21,025	13,733	124,046
Treasury shares	(77,292)	(57,989)	(523,796)
Retained earnings	708,291	752,248	6,794,764
Other components of equity	91,848	116,836	1,055,340
<b>Equity attributable to owners of parent</b>	<b>765,152</b>	<b>846,108</b>	<b>7,642,566</b>
<b>Non-controlling interests</b>	<b>51</b>	<b>18,442</b>	<b>166,583</b>
<b>Total equity</b>	<b>765,203</b>	<b>864,550</b>	<b>7,809,149</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Lease liabilities	4,791	4,608	41,631
Other financial liabilities	4,179	5,242	47,353
Retirement benefit liability	16,089	16,318	147,400
Deferred tax liabilities	1,949	7,749	69,998
Other non-current liabilities	362	341	3,088
<b>Total non-current liabilities</b>	<b>27,372</b>	<b>34,261</b>	<b>309,471</b>
<b>Current liabilities</b>			
Lease liabilities	3,361	3,379	30,523
Trade payables	10,763	9,902	89,450
Other financial liabilities	17,557	21,383	193,148
Income taxes payable	21,886	28,033	253,211
Other current liabilities	27,551	37,481	338,559
<b>Total current liabilities</b>	<b>81,119</b>	<b>100,180</b>	<b>904,891</b>
<b>Total liabilities</b>	<b>108,492</b>	<b>134,442</b>	<b>1,214,363</b>
<b>Total equity and liabilities</b>	<b>873,695</b>	<b>998,992</b>	<b>9,023,512</b>



## Consolidated statement of profit or loss

		(Millions of yen)	(Thousands of U.S. dollars)
	Year ended March 31, 2020	Year ended March 31, 2021	Year ended March 31, 2021
<b>Revenue</b>	¥333,371	¥297,177	\$2,684,290
Cost of sales	(56,782)	(52,523)	(474,426)
<b>Gross profit</b>	276,589	244,654	2,209,864
Selling, general and administrative expenses	(95,094)	(91,902)	(830,122)
Research and development expenses	(47,949)	(54,249)	(490,018)
Amortization of intangible assets associated with products	(3,255)	(3,209)	(28,987)
Other income	4,291	26,403	238,490
Other expenses	(3,951)	(4,257)	(38,456)
<b>Operating profit</b>	130,628	117,438	1,060,772
Finance income	30,504	26,522	239,564
Finance costs	(2,616)	(941)	(8,504)
<b>Profit before tax</b>	158,516	143,018	1,291,833
Income tax expense	(36,322)	(30,956)	(279,622)
<b>Profit</b>	122,194	112,061	1,012,210
<b>Profit attributable to</b>			
Owners of parent	122,193	111,858	1,010,377
Non-controlling interests	1	203	1,834
<b>Profit</b>	122,194	112,061	1,012,210
<b>Earnings per share</b>		(Yen)	(U.S. dollars)
Basic earnings per share	395.71	365.03	\$3.30
Diluted earnings per share	395.28	364.89	3.30

## Consolidated statement of comprehensive income

		(Millions of yen)	(Thousands of U.S. dollars)
	Year ended March 31, 2020	Year ended March 31, 2021	Year ended March 31, 2021
<b>Profit</b>	¥122,194	¥112,061	\$1,012,210
<b>Other comprehensive income</b>			
Items that will not be reclassified to profit or loss			
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	(62,544)	(4,677)	(42,253)
Remeasurements of defined benefit plans	503	(96)	(871)
Total of items that will not be reclassified to loss	(62,040)	(4,774)	(43,124)
Items that may be reclassified to profit or loss			
Exchange differences on translation of foreign operations	(26,247)	36,049	325,624
Effective portion of cash flow hedges	2,474	(5,828)	(52,644)
Total of items that may be reclassified to profit or loss	(23,772)	30,221	272,980
Total other comprehensive (loss) income, net of tax	(85,813)	25,447	229,856
<b>Comprehensive income</b>	36,381	137,509	1,242,066
<b>Comprehensive income attributable to</b>			
Owners of parent	36,594	137,407	1,241,150
Non-controlling interests	(213)	101	916
<b>Comprehensive income</b>	36,381	137,509	1,242,066

## Consolidated statement of changes in equity

(Millions of yen)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Equity attributable to owners of parent	Non-controlling interests	Total equity
<b>Balance as of April 1, 2019</b>	¥21,279	¥21,277	¥(28,882)	¥613,483	¥181,616	¥808,774	¥ 4,313	¥813,087
Profit				122,193		122,193	1	122,194
Total other comprehensive income, net of tax					(85,598)	(85,598)	(214)	(85,813)
Comprehensive income	—	—	—	122,193	(85,598)	36,594	(213)	36,381
Purchase of treasury shares			(50,012)			(50,012)		(50,012)
Disposal of treasury shares		(509)	1,602			1,092		1,092
Dividends				(31,134)		(31,134)		(31,134)
Increase by business combination						—	682	682
Changes in ownership interest in subsidiaries		(162)				(162)	(4,779)	(4,942)
Transfer from other components of equity to retained earnings				4,169	(4,169)	—		—
Other		420		(420)		0	49	49
<b>Balance as of March 31, 2020</b>	21,279	21,025	(77,292)	708,291	91,848	765,152	51	765,203
Profit				111,858		111,858	203	112,061
Total other comprehensive income, net of tax					25,548	25,548	(101)	25,447
Comprehensive income	—	—	—	111,858	25,548	137,407	101	137,509
Purchase of treasury shares			(50,013)			(50,013)		(50,013)
Disposal of treasury shares		(4,705)	38,404			33,698		33,698
Cancellation of treasury shares		(30,912)	30,912			—		—
Dividends				(32,543)		(32,543)		(32,543)
Changes in scope of consolidation						—	10,696	10,696
Changes in ownership interest in subsidiaries		(7,593)				(7,593)	7,593	—
Transfer from other components of equity to retained earnings				71	(71)	—		—
Other		35,919		(35,430)	(488)	(0)		(0)
<b>Balance as of March 31, 2021</b>	21,279	13,733	(57,989)	752,248	116,836	846,108	18,442	864,550

(Thousands of U.S. dollars)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Equity attributable to owners of parent	Non-controlling interests	Total equity
<b>Balance as of March 31, 2020</b>	\$192,212	\$189,911	\$(698,152)	\$6,397,723	\$ 829,628	\$6,911,322	\$ 463	\$6,911,785
Profit				1,010,377		1,010,377	1,834	1,012,210
Total other comprehensive income, net of tax					230,774	230,774	(918)	229,856
Comprehensive income	—	—	—	1,010,377	230,774	1,241,150	916	1,242,066
Purchase of treasury shares			(451,753)			(451,753)		(451,753)
Disposal of treasury shares		(42,506)	346,893			304,388		304,388
Cancellation of treasury shares		(279,216)	279,216			—		—
Dividends				(293,952)		(293,952)		(293,952)
Changes in scope of consolidation						—	96,616	96,616
Changes in ownership interest in subsidiaries		(68,588)				(68,588)	68,588	—
Transfer from other components of equity to retained earnings				645	(645)	—		—
Other		324,445		(320,029)	(4,416)	(1)		(1)
<b>Balance as of March 31, 2021</b>	192,212	124,046	(523,796)	6,794,764	1,055,340	7,642,566	166,583	7,809,149

## Consolidated statement of cash flows

	Year ended March 31, 2020	(Millions of yen) Year ended March 31, 2021	(Thousands of U.S. dollars) Year ended March 31, 2021
<b>Cash flows from operating activities</b>			
Profit before tax	¥158,516	¥143,018	\$1,291,833
Depreciation and amortization	14,115	14,779	133,494
Impairment losses	100	825	7,452
Finance income and finance costs	(29,233)	(25,836)	(233,370)
Decrease in trade and other receivables	21,371	2,993	27,036
Decrease (increase) in inventories	1,158	(3,435)	(31,032)
Decrease in trade and other payables	(5,747)	(2,380)	(21,506)
Other	(9,202)	(16,524)	(149,258)
<b>Subtotal</b>	<b>151,078</b>	<b>113,438</b>	<b>1,024,649</b>
Interest and dividends received	29,565	28,111	253,917
Interest paid	(348)	(256)	(2,314)
Income taxes paid	(48,354)	(32,254)	(291,341)
<b>Net cash provided by operating activities</b>	<b>131,940</b>	<b>109,039</b>	<b>984,911</b>
<b>Cash flows from investing activities</b>			
Payments into time deposits	(200,827)	(230,468)	(2,081,732)
Proceeds from withdrawal of time deposits	174,672	269,696	2,436,059
Purchase of property, plant and equipment	(8,945)	(28,182)	(254,559)
Proceeds from sale of property, plant and equipment	3,427	45	408
Purchase of intangible assets	(2,823)	(4,762)	(43,015)
Payments for acquisition of subsidiaries	(4,525)	(3,636)	(32,849)
Purchase of investments in associates	(4,252)	—	—
Purchase of investments	(99,630)	(120,478)	(1,088,237)
Proceeds from sale of investments	119,485	116,265	1,050,178
Other	(5,725)	(3,739)	(33,780)
<b>Net cash used in investing activities</b>	<b>(29,144)</b>	<b>(5,261)</b>	<b>(47,528)</b>
<b>Cash flows from financing activities</b>			
Repayments of lease liabilities	(3,544)	(3,648)	(32,957)
Purchase of treasury shares	(50,159)	(50,134)	(452,847)
Proceeds from sale of treasury shares	—	33,534	302,902
Dividends paid	(31,122)	(32,529)	(293,829)
Payments for acquisition of interests in subsidiaries from non-controlling interests	(3,367)	(1,575)	(14,233)
Capital contribution from non-controlling interests	49	10,464	94,519
Other	(30)	(0)	(7)
<b>Net cash used in financing activities</b>	<b>(88,174)</b>	<b>(43,891)</b>	<b>(396,452)</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>(1,560)</b>	<b>7,425</b>	<b>67,075</b>
<b>Net increase in cash and cash equivalents</b>	<b>13,060</b>	<b>67,312</b>	<b>608,007</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>195,800</b>	<b>208,861</b>	<b>1,886,560</b>
<b>Cash and cash equivalents at end of period</b>	<b>¥208,861</b>	<b>¥276,173</b>	<b>\$2,494,567</b>

## Non-Financial Data

	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2021	Remark	
<b>Information on the number of employees</b> (Information about only Shionogi & Co., Ltd. unless otherwise stated)	No. of employees						
	Consolidated	5,511 persons	5,120 persons	5,233 persons (4,554 persons)	5,222 persons (4,527 persons)	5,485 persons (4,617 persons)	The figure in parentheses is calculated for domestic consolidated companies.
	Shionogi & Co., Ltd.	3,911 persons	3,677 persons	3,596 persons	2,667 persons	2,589 persons	
	Rate of female employees	28.8%	27.8%	28.1% (32.2%)	24.1% (32.2%)	25.4% (32.7%)	The figure in parentheses is calculated for domestic consolidated companies.
	Average age						
	Total	41.7 years old	41.4 years old	41.7 years old	41.3 years old	41.2 years old	Excluding seconded persons
	Male	42.2 years old	41.9 years old	42.2 years old	41.9 years old	41.8 years old	
	Female	40.6 years old	40.0 years old	40.4 years old	39.2 years old	39.3 years old	
	Length of service						
	Total	17.4 years	17.3 years	17.3 years	15.9 years	15.7 years	Excluding seconded persons
	Male	17.1 years	16.9 years	17.1 years	16.1 years	16.0 years	
	Female	18.1 years	17.4 years	17.8 years	15.0 years	15.0 years	
	Average salary	9,276,750 yen	9,193,748 yen	9,042,130 yen	9,431,304 yen	9,028,578 yen	
	No. of new recruits						
	Total	91 persons	110 persons	101 persons	94 persons	71 persons	Recruits who will enter the company on April 1 of the following fiscal year
	Male	61 persons	71 persons	59 persons	56 persons	37 persons	
	Female	30 persons	39 persons	42 persons	38 persons	34 persons	
	Turnover rate of recruits enrolled for three years	6.5%	6.5%	3.0%	4.5%	6.0%	Recruit who entered the company on April 1 three years ago
	Turnover rate of employees	1.4%	1.9%	1.6%	1.9%	1.9%	Excluding retired persons
	No. of labor union members	2,948 persons Rate of union members: 100%	2,758 persons Rate of union members: 100%	3,012 persons Rate of union members: 100%	2,806 persons Rate of union members: 100%	2,728 persons Rate of union members: 100%	
	Employment rate of people with disabilities	2.3%	2.2%	2.0% (2.5%)	2.0% (2.6%)	2.0% (2.7%)	As of the end of March. The figure in parentheses is calculated for special cases in affiliated companies. Shionogi Smile Heart Co., Ltd. established in April 2018 and certified as a special subsidiary company in July 2018.
No. of female managers	51 persons	47 persons	40 persons (63 persons)	39 persons (68 persons)	37 persons (71 persons)	As of April 1 of the following fiscal year. The figure in parentheses is calculated for domestic consolidated companies.	
Rate of female managers	8.4%	8.0%	9.9% (10.0%)	10.7% (11.4%)	10.4% (11.5%)	As of April 1 of the following fiscal year. The figure in parentheses is calculated for domestic consolidated companies. Target: 10% (Domestic consolidation at the end of March 2021)	
Rate of female heads of organizations	6.7%	7.7%	8.6%	14.3%	12.7%	As of April 1 of the following fiscal year	
Rate of female corporate officers	2/12 16.7%	1/14 7.1%	1/13 7.7%	0/10 0.0%	0/10 0.0%	As of April 1 of the following fiscal year	
Rate of female members of the Board	16.7%	16.7%	16.7%	16.7%	40.0%	As of April 1 of the following fiscal year	
<b>Information on labor management</b> (Shionogi & Co., Ltd.)	Annual regular working hours for employees	1,860 hours	1,860 hours	1,852 hours	1,845 hours	1,837 hours	
	No. of paid holidays	Up to 24 days	Up to 24 days	Up to 24 days	Up to 21 days	Up to 21 days	The number of legal annual holidays based on the Labor Standards Act is up to 20 days.
	Average No. of paid holidays taken by employees	13.6 days	12.0 days	12.5 days	12.6 days	12.6 days	
	Acquisition rate of childcare leave						
	Female	100%	100%	100%	100%	100%	
	Male	17.4%	21.0%	24.2%	32.8%	41.1%	Rate of employees who have taken childcare leave during the year when their baby was born
	No. of employees who have taken nursing care leave						
	Female	4 persons	4 persons	2 persons	4 persons	1 persons	Total number
	Male	0 persons	0 persons	0 persons	1 persons	0 persons	
	No. of employees who have worked on short work hours due to child rearing						
	Female	173 persons	162 persons	119 persons	136 persons	130 persons	Total number
	Male	2 persons	1 persons	1 persons	1 persons	1 persons	
	Volunteer leave	0 persons	1 persons	0 persons	1 persons	1 persons	
	Leave for bone marrow transplant donors	1 persons	0 persons	0 persons	1 persons	1 persons	
	Frequency rate	0.25	0.39	0.81	0.19	0.19	
Severity rate	0.004	0.003	0.018	0.0002	0.0047		
Legal violation / Administrative guidance	0 case	0 case	0 case	0 case	0 case		
<b>Health</b> (Shionogi & Co., Ltd.)	Smoking rate	17.1%	16.4%	15.2%	14.2%	11.0%	
	Rate of stress check attendance	94%	94%	96%	95%	94%	
	Participation rate in a healthy walk	35.4%	42.2%	41.5%	41.5%	40.4%	
	Rate of health checkup attendance	100%	100%	100%	100%	100%	
	Rate of employees on leave due to mental disorders	0.5%	0.4%	0.4%	0.5%	0.6%	
<b>Environment</b> (Domestic consolidated companies)	GHG emissions (Scope 1 and 2)	95,720 tons-CO <sub>2</sub>	90,136 tons-CO <sub>2</sub>	82,711 tons-CO <sub>2</sub>	76,939 tons-CO <sub>2</sub>	75,339 tons-CO <sub>2</sub>	Scope: Domestic consolidated companies (excluding Nagase Medicals Co., Ltd.) and the Nanjing Plant of C&O Pharmaceutical Technology (Holdings) Limited
	Total energy consumption (Thousand)	1,818 GJ	1,734 GJ	1,678 GJ	1,651 GJ	1,665 GJ	
	Water use (Thousand)	1,528 m <sup>3</sup>	1,389 m <sup>3</sup>	1,315 m <sup>3</sup>	1,263 m <sup>3</sup>	1,217 m <sup>3</sup>	
	Amount of waste generated	3,820 tons	3,486 tons	3,824 tons	3,062 tons	4,180 tons	
	Recycling rate	79%	78%	81%	83%	87%	
	Landfill rate	1.3%	1.0%	0.8%	1.0%	0.6%	
	Type 1 chemicals designated under the PRTR Act						
	Amount handled	289 tons	251 tons	274 tons	203 tons	257 tons	
	Amount released	63 tons	35 tons	43 tons	34 tons	94 tons	
	Amount transferred	148 tons	177 tons	156 tons	131 tons	114 tons	
No. of complaints about the environment	1 case	2 cases	1 case	0 case	0 case		
<b>Compliance</b> (Domestic consolidated companies)	Number of disciplinary dismissals of employees due to violations of laws for the prevention of corruption and bribery*	—	—	0 case	0 case	0 case	*FCPA in the US, Bribery Act in the UK, Unfair Competition Prevention Act in Japan
	Costs related to fines, punishments, and settlements of violations of laws for the prevention of corruption and bribery*	—	—	0 yen	0 yen	0 yen	
<b>Other</b>	Market capitalization (Shionogi & Co., Ltd.)	¥1,891.9 billion	¥1,743.8 billion	¥2,170.5 billion	¥1,684.4 billion	¥1,854.6 billion	
	Donations (consolidated)	¥1,031 million	¥1,020 million	¥949 million	¥1,065 million	¥1,069 million	
	Code of Conduct Rate of digital signature*					100%	*Applicable organizations: Shionogi & Co., Ltd. and domestic Group companies
	Code of Conduct Rate of training participation*					100%	

# Corporate Information

## Corporate Data (As of March 31, 2021)

Company Name	Shionogi & Co., Ltd
Established	March 17, 1878
Incorporated	June 5, 1919
Paid-in Capital	¥21,279 million
Number of Employees	5,485 (Consolidated)
Fiscal Year-End	March 31
Website	<a href="https://www.shionogi.com/global/en/">https://www.shionogi.com/global/en/</a>

## Stock Information (As of March 31, 2021)

### ■ Stock (Securities) Listings:

Tokyo (#4507) (Shares listed in 1949)

### ■ Stock Status:


Common Stock Authorized: 1,000,000,000 shares

Issued: 311,586,165 shares  
(Including 10,122,444 shares of treasury stock)

Note: On April 6, 2020, the Company cancelled 5,200 thousand shares of treasury stock.

Number of shareholders: 56,510

### ■ Shareholder Composition



Note: Treasury shares included in Individuals.

### ■ Major Shareholders

Name	Number of shares (Thousands)	Percentage of total shares (%)
The Master Trust Bank of Japan, Ltd. (Trust account)	41,349	13.71
Custody Bank of Japan, Ltd. (Trust account)	18,663	6.19
Sumitomo Life Insurance Company	18,604	6.17
SMBC Trust Bank Ltd. (as a trustee for retirement benefit of Sumitomo Mitsui Banking Corporation)	9,485	3.14
JP MORGAN CHASE BANK 385632	9,287	3.08
Nippon Life Insurance Company	8,409	2.78
Custody Bank of Japan, Ltd. (Trust account 7)	7,484	2.48
BNYM TREATY DTT 15	6,982	2.31
BANK OF CHINA (HONG KONG) LIMITED-PING AN LIFE INSURANCE COMPANY OF CHINA, LIMITED	6,356	2.10
NORTHERN TRUST CO. (AVFC) SUB A/C AMERICAN CLIENTS	4,820	1.59

#### Notes:

- The Company owns 10,122,444 shares of treasury shares but the Company is not included in the major shareholders listed above (top 10).
- The percentage of total is calculated as the proportion of shares to 301,463,721 shares of total issued stock (excluding 10,122,444 shares of treasury shares).